Moderna Has Found Another Virus To Monetize

0
148

Moderna is back at the public trough with another experimental mRNA vaccine, this time targeting the Bundibugyo strain of Ebola. CBC reports that Health Canada has authorized a Phase 1 trial of mRNA-1469 at three Canadian sites involving about 80 adults. Canada has never recorded a single Ebola case, and its government admits the risk to the general population is low, yet healthy Canadians will supply the human data for a product intended primarily for a third-world African nation.

As of August 1, there were 3,748 confirmed cases and 1,657 deaths in the Democratic Republic of Congo. There is no approved vaccine specifically targeting Bundibugyo Ebola, but Moderna is not financing this humanitarian venture alone. The Coalition for Epidemic Preparedness Innovations has pledged up to $50 million for preclinical research, Phase 1 testing, and manufacturing doses before the early trial…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here